A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Shuai Xia, Lei Yan, Wei Xu, Anurodh Shankar Agrawal, Abdullah Algaissi, Chien-Te Tseng, Qian Wang, Lanying Du, Wenjie Tan, Ian A. Wilson, Shibo Jiang, Bei Yang, Lu Lu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Continuously emerging highly pathogenic human coronaviruses (HCoVs) remain a major threat to human health, as illustrated in past SARS-CoV and MERS-CoV outbreaks. The development of a drug with broad-spectrum HCoV inhibitory activity would address this urgent unmet medical need. Although previous studies have suggested that the HR1 of HCoV spike (S) protein is an important target site for inhibition against specific HCoVs, whether this conserved region could serve as a target for the development of broad-spectrum pan-CoV inhibitor remains controversial. Here, we found that peptide OC43-HR2P, derived from the HR2 domain of HCoV-OC43, exhibited broad fusion inhibitory activity against multiple HCoVs. EK1, the optimized form of OC43-HR2P, showed substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties. Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-HCoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.

Original languageEnglish (US)
Article numbereaav4580
JournalScience Advances
Volume5
Issue number4
DOIs
StatePublished - Jan 1 2019

Fingerprint

spikes
inhibitors
fusion
helices
bundles
health
peptides
emerging
drugs
proteins
crystal structure

ASJC Scopus subject areas

  • Physics and Astronomy (miscellaneous)

Cite this

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. / Xia, Shuai; Yan, Lei; Xu, Wei; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Tseng, Chien-Te; Wang, Qian; Du, Lanying; Tan, Wenjie; Wilson, Ian A.; Jiang, Shibo; Yang, Bei; Lu, Lu.

In: Science Advances, Vol. 5, No. 4, eaav4580, 01.01.2019.

Research output: Contribution to journalArticle

Xia, S, Yan, L, Xu, W, Agrawal, AS, Algaissi, A, Tseng, C-T, Wang, Q, Du, L, Tan, W, Wilson, IA, Jiang, S, Yang, B & Lu, L 2019, 'A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike', Science Advances, vol. 5, no. 4, eaav4580. https://doi.org/10.1126/sciadv.aav4580
Xia, Shuai ; Yan, Lei ; Xu, Wei ; Agrawal, Anurodh Shankar ; Algaissi, Abdullah ; Tseng, Chien-Te ; Wang, Qian ; Du, Lanying ; Tan, Wenjie ; Wilson, Ian A. ; Jiang, Shibo ; Yang, Bei ; Lu, Lu. / A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. In: Science Advances. 2019 ; Vol. 5, No. 4.
@article{22e06a4fc2e6417da81d75c1bbbbde92,
title = "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike",
abstract = "Continuously emerging highly pathogenic human coronaviruses (HCoVs) remain a major threat to human health, as illustrated in past SARS-CoV and MERS-CoV outbreaks. The development of a drug with broad-spectrum HCoV inhibitory activity would address this urgent unmet medical need. Although previous studies have suggested that the HR1 of HCoV spike (S) protein is an important target site for inhibition against specific HCoVs, whether this conserved region could serve as a target for the development of broad-spectrum pan-CoV inhibitor remains controversial. Here, we found that peptide OC43-HR2P, derived from the HR2 domain of HCoV-OC43, exhibited broad fusion inhibitory activity against multiple HCoVs. EK1, the optimized form of OC43-HR2P, showed substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties. Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-HCoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.",
author = "Shuai Xia and Lei Yan and Wei Xu and Agrawal, {Anurodh Shankar} and Abdullah Algaissi and Chien-Te Tseng and Qian Wang and Lanying Du and Wenjie Tan and Wilson, {Ian A.} and Shibo Jiang and Bei Yang and Lu Lu",
year = "2019",
month = "1",
day = "1",
doi = "10.1126/sciadv.aav4580",
language = "English (US)",
volume = "5",
journal = "Indian Journal of Pure and Applied Physics",
issn = "0019-5596",
publisher = "National Institute of Science Communication and Information Resources (NISCAIR)",
number = "4",

}

TY - JOUR

T1 - A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

AU - Xia, Shuai

AU - Yan, Lei

AU - Xu, Wei

AU - Agrawal, Anurodh Shankar

AU - Algaissi, Abdullah

AU - Tseng, Chien-Te

AU - Wang, Qian

AU - Du, Lanying

AU - Tan, Wenjie

AU - Wilson, Ian A.

AU - Jiang, Shibo

AU - Yang, Bei

AU - Lu, Lu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Continuously emerging highly pathogenic human coronaviruses (HCoVs) remain a major threat to human health, as illustrated in past SARS-CoV and MERS-CoV outbreaks. The development of a drug with broad-spectrum HCoV inhibitory activity would address this urgent unmet medical need. Although previous studies have suggested that the HR1 of HCoV spike (S) protein is an important target site for inhibition against specific HCoVs, whether this conserved region could serve as a target for the development of broad-spectrum pan-CoV inhibitor remains controversial. Here, we found that peptide OC43-HR2P, derived from the HR2 domain of HCoV-OC43, exhibited broad fusion inhibitory activity against multiple HCoVs. EK1, the optimized form of OC43-HR2P, showed substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties. Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-HCoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.

AB - Continuously emerging highly pathogenic human coronaviruses (HCoVs) remain a major threat to human health, as illustrated in past SARS-CoV and MERS-CoV outbreaks. The development of a drug with broad-spectrum HCoV inhibitory activity would address this urgent unmet medical need. Although previous studies have suggested that the HR1 of HCoV spike (S) protein is an important target site for inhibition against specific HCoVs, whether this conserved region could serve as a target for the development of broad-spectrum pan-CoV inhibitor remains controversial. Here, we found that peptide OC43-HR2P, derived from the HR2 domain of HCoV-OC43, exhibited broad fusion inhibitory activity against multiple HCoVs. EK1, the optimized form of OC43-HR2P, showed substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties. Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-HCoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.

UR - http://www.scopus.com/inward/record.url?scp=85064729014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064729014&partnerID=8YFLogxK

U2 - 10.1126/sciadv.aav4580

DO - 10.1126/sciadv.aav4580

M3 - Article

C2 - 30989115

AN - SCOPUS:85064729014

VL - 5

JO - Indian Journal of Pure and Applied Physics

JF - Indian Journal of Pure and Applied Physics

SN - 0019-5596

IS - 4

M1 - eaav4580

ER -